Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

AIS 2024

- PMLiVE

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

- PMLiVE

Lilly and Indiana University collaborate to expand clinical trial access

The five-year agreement includes a focus on R&D for Alzheimer’s disease

- PMLiVE

Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

While the trials did not meet their primary endpoints, they highlighted important biomarker findings

- PMLiVE

Vandria announces positive phase 1 data for Alzheimer’s treatment

Trial data showed that VNA-318 has the ability to penetrate the brain

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

- PMLiVE

Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

- PMLiVE

Lilly’s early Alzheimer’s disease treatment approved in the EU

Marketing authorisation follows positive late-stage trial results

- PMLiVE

Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

- PMLiVE

Medscape Online Continuing Medical Education Led to New Diagnoses in Alzheimer’s Disease

Medscape Education has recently published a study looking at the real-world impact of online continuing medical education on Alzheimer's disease diagnosis. Read the full article here.  The study, published in...

Medscape Education

- PMLiVE

AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition

The deal includes a candidate in phase 1 development for Alzheimer's disease

- PMLiVE

Making at Impact at the Alliance Industry Summit

The Medscape team will be returning to the Alliance Industry Summit in Philadelphia this year, bringing with them Best in Class Outcomes and support for the event. As part of...

Medscape Education

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug shows continued cognitive improvement in long-term study

Leqembi was granted traditional US approval last year to treat patients in the early stages of the disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links